📗 Cite This Artifact
ID: hypothesis-h-baba5269
Hypothesis
Partial Neuronal Reprogramming via Modified Yamanaka Cocktail
Partial Neuronal Reprogramming via Modified Yamanaka Cocktail starts from the claim that modulating OCT4 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 37 cit🗣 3 debates✓ 17 support✗ 10 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Partial Neuronal Reprogramming via Modified Yamanaka Cocktail starts from the claim that modulating OCT4 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "The hypothesis of partial neuronal reprogramming via a modified Yamanaka cocktail represents a paradigm shift in approaching neurodegeneration through epigenetic rejuvenation while preserving neuronal identity. This approach leverages the fundamental principle that cellular aging is largely driven by progressive epigenetic modifications rather than irreversible genetic damage, making it theoretically reversible through controlled reprogramming interventions. Molecular Mechanism of Action: The central mechanism involves OCT4-mediated chromatin remodeling operating through multiple interconnected pathways. OCT4, as a POU-domain transcription factor, functions as a pioneer transcription factor capable of binding to nucleosomal DNA and recruiting chromatin remodeling complexes including SWI/SNF, NuRD, and CoREST complexes....
Mechanistic Overview
Partial Neuronal Reprogramming via Modified Yamanaka Cocktail starts from the claim that modulating OCT4 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "The hypothesis of partial neuronal reprogramming via a modified Yamanaka cocktail represents a paradigm shift in approaching neurodegeneration through epigenetic rejuvenation while preserving neuronal identity. This approach leverages the fundamental principle that cellular aging is largely driven by progressive epigenetic modifications rather than irreversible genetic damage, making it theoretically reversible through controlled reprogramming interventions. Molecular Mechanism of Action: The central mechanism involves OCT4-mediated chromatin remodeling operating through multiple interconnected pathways. OCT4, as a POU-domain transcription factor, functions as a pioneer transcription factor capable of binding to nucleosomal DNA and recruiting chromatin remodeling complexes including SWI/SNF, NuRD, and CoREST complexes. In the context of neuronal reprogramming, OCT4 expression at 10-30% of pluripotency levels initiates chromatin relaxation without triggering the full pluripotency gene regulatory network. The modified cocktail excludes c-MYC to prevent oncogenic transformation and includes SOX2 and KLF4 at reduced levels (20-40% of standard reprogramming concentrations). SOX2, sharing heterodimerization capacity with OCT4, enhances chromatin accessibility at neuronal enhancer regions while KLF4 facilitates the removal of repressive histone marks, particularly H3K9me3 and H3K27me3. The addition of ASCL1 serves as a neuronal-specific pioneer factor that maintains chromatin accessibility at neuronal gene loci, while BRN2 (POU3F2) acts as a neuronal identity safeguard, preventing dedifferentiation beyond intermediate progenitor states. Upstream Regulators and Downstream Effectors: Upstream regulation involves the controlled activation of reprogramming factors through doxycycline-inducible promoter systems, allowing precise temporal control. The pathway is modulated by endogenous neuronal factors including REST/NRSF, which maintains neuronal gene silencing in non-neuronal contexts but becomes permissive under partial reprogramming conditions. MicroRNA networks, particularly miR-124 and miR-9 families, provide additional regulatory layers that favor neuronal identity maintenance. Downstream effectors include the TET family enzymes (TET1, TET2, TET3) which are recruited by OCT4 to promote active DNA demethylation at CpG sites associated with youthful neuronal function. The pathway activates DNMT3L and inhibits DNMT1/3A to reset DNA methylation patterns. Chromatin remodeling leads to reactivation of silenced neuronal genes including BDNF, CREB, ARC, and synaptic plasticity genes while simultaneously rejuvenating mitochondrial biogenesis through PGC-1α activation. Connection to Disease Pathology: Neurodegeneration involves progressive accumulation of repressive epigenetic marks that silence neuroprotective genes and activate inflammatory pathways. In Alzheimer's disease, hypermethylation of BDNF and CREB promoters contributes to synaptic dysfunction, while altered H3K4me3 patterns affect tau and amyloid processing genes. The partial reprogramming approach specifically targets these age-associated epigenetic changes, potentially reversing the molecular basis of neurodegeneration rather than merely treating symptoms. The mechanism addresses multiple pathological hallmarks simultaneously: restoring synaptic plasticity genes, reactivating stress response pathways, improving mitochondrial function through epigenetic control of OXPHOS genes, and reducing neuroinflammation by resetting microglial activation states through paracrine signaling from rejuvenated neurons. Therapeutic Window and Dosing Considerations: The therapeutic window requires precise optimization of factor levels and timing to achieve rejuvenation without losing neuronal identity. Based on preliminary studies, OCT4 expression should be maintained at 15-25% of embryonic stem cell levels for 48-72 hour pulses, followed by 96-120 hour rest periods. This pulsed approach allows epigenetic remodeling while permitting neuronal identity factors to reassert control. Dosing considerations involve vector copy number (optimal range 2-5 copies per cell), induction timing (3-4 cycles for maximal benefit without toxicity), and regional specificity (hippocampal neurons may require different protocols than cortical neurons due to distinct chromatin landscapes). The approach requires careful monitoring of reprogramming depth using established biomarkers including methylation age clocks and chromatin accessibility profiles. Comparison with Existing Approaches: Current neurodegeneration treatments focus on symptomatic relief or single pathway modulation (cholinesterase inhibitors, amyloid-targeting therapies), whereas partial reprogramming addresses fundamental aging processes. Unlike stem cell replacement strategies that require cell transplantation, this approach rejuvenates endogenous neurons in situ, preserving established neural circuits and avoiding integration challenges. Compared to small molecule approaches targeting individual epigenetic enzymes (HDAC inhibitors, DNMT inhibitors), partial reprogramming provides coordinated, comprehensive epigenetic remodeling. The approach offers advantages over gene therapy targeting single factors by addressing the multifactorial nature of neuronal aging through coordinated transcriptional network reset. Potential Biomarkers for Efficacy: Epigenetic age biomarkers include the Horvath clock and neural-specific methylation clocks measuring biological age reversal. Functional biomarkers encompass synaptic protein expression (PSD95, synaptophysin, SNAP25), dendritic spine density measurements, and electrophysiological parameters including long-term potentiation magnitude and action potential properties. Molecular biomarkers include chromatin accessibility changes measured by ATAC-seq, histone modification patterns (H3K4me3/H3K27me3 ratios), and single-cell RNA sequencing profiles demonstrating youthful gene expression patterns while maintaining neuronal identity markers. Functional outcomes include cognitive assessments, neuroimaging measures of brain volume and connectivity, and CSF biomarkers reflecting neuronal health. Testable Predictions: The hypothesis predicts that partial reprogramming will: (1) reduce DNA methylation age by 20-40% in treated neurons while maintaining >95% neuronal marker expression, (2) restore synaptic plasticity to youthful levels as measured by LTP amplitude and duration, (3) improve mitochondrial function indicated by increased ATP production and reduced ROS levels, (4) enhance cognitive performance in aged animal models by 30-50% across multiple domains, and (5) demonstrate dose-dependent effects with optimal efficacy at specific factor concentration ranges. Additional predictions include restoration of circadian rhythm gene expression, improved stress resistance, and enhanced neurogenesis in neurogenic niches through paracrine effects from rejuvenated neurons. Key Experimental Model Systems: Primary experimental models include aged primary neurons from 18-24 month old mice and rats, allowing assessment of reprogramming in naturally aged cells. Human iPSC-derived neurons subjected to aging protocols (oxidative stress, mitochondrial dysfunction) provide translational relevance. Organotypic brain slice cultures from aged animals enable assessment of reprogramming effects within preserved neural circuit architecture. In vivo models encompass naturally aged mice (18-24 months), accelerated aging models (SAMP8, progerin-expressing mice), and disease-specific models (5xFAD Alzheimer's mice, MPTP Parkinson's models). Non-human primate studies using aged macaques would provide critical translational data given the evolutionary conservation of reprogramming mechanisms and brain structure similarity to humans. Advanced model systems include brain organoids derived from aged human fibroblasts, allowing assessment of species-specific responses, and microfluidic culture systems enabling precise factor delivery control and real-time monitoring of reprogramming progression. These models collectively provide the experimental framework necessary to validate, optimize, and translate partial neuronal reprogramming approaches toward clinical application. Challenges and Risk Mitigation Challenge 1: Oncogenic Risk. Even modified Yamanaka factors carry theoretical cancer risk. OCT4, SOX2, and KLF4 are expressed in various cancers. Mitigation: The modified cocktail excludes c-MYC. Use self-limiting expression systems with built-in kill switches (inducible caspase-9). Implement strict temporal control through doxycycline-responsive promoters. Long-term safety monitoring in non-human primates (minimum 2 years) before human trials. Challenge 2: Loss of Neuronal Identity. Excessive reprogramming could push neurons into dedifferentiation, losing established synaptic connections. Mitigation: ASCL1 and BRN2 serve as neuronal identity safeguards. Monitor neuronal identity markers (NeuN, MAP2, synapsin) in real-time. If neuronal marker expression drops below 90% of baseline, terminate the reprogramming cycle. Single-cell RNA sequencing at each cycle endpoint confirms identity preservation. Challenge 3: Immune Response to Viral Vectors. AAV-mediated delivery may trigger immune responses, limiting repeated dosing. Mitigation: Use non-viral delivery systems (lipid nanoparticles carrying mRNA) for repeatable dosing without immunogenicity concerns. mRNA-based delivery provides inherently transient expression, adding a natural safety layer. Challenge 4: Heterogeneous Response Across Neuronal Subtypes. Different neuronal populations have distinct chromatin landscapes and may respond differently. Mitigation: Develop subtype-specific promoter systems. Characterize response heterogeneity in organoid models before in vivo application. Accept that initial applications may target specific populations (e.g., hippocampal neurons in AD, dopaminergic neurons in PD). Resource Requirements and Timeline - Cocktail optimization in human iPSC-derived neurons: 18 months, $4-6M - Safety validation in rodent models (12-month follow-up): 24 months, $8-12M - Delivery platform development (LNP-mRNA or AAV): 24 months, $10-15M - Non-human primate studies (24-month follow-up): 36 months, $15-25M - IND-enabling studies and regulatory interactions: 18 months, $8-12M - Phase 1/2a first-in-human trial: 36 months, $30-50M - Total to proof-of-concept: $75-120M over 10-12 years Competitive Landscape - Altos Labs: Well-funded startup focused on cellular rejuvenation through reprogramming. Primary focus on peripheral tissues; neuronal applications in early research. - Turn Biotechnologies: mRNA-based partial reprogramming (ERA platform). Demonstrated epigenetic age reversal in human cells but not yet in neurons. - Shift Bioscience: Working on partial reprogramming with machine learning-guided optimization. - Retro Biosciences: Focused on autophagy and partial reprogramming for longevity. Key differentiation: This hypothesis is uniquely positioned by its neuronal-specific modifications — ASCL1 and BRN2 as identity safeguards, c-MYC exclusion for safety, and pulsed dosing optimized for post-mitotic cells. While competitors pursue broad tissue rejuvenation, this specifically solves reprogramming of non-dividing neurons without losing identity. Regulatory Pathway The regulatory pathway would follow the gene therapy framework (CBER). Key considerations include long-term follow-up requirements (15 years recommended), tumorigenic risk assessment, and potential for RMAT designation. The combination of unmet need and novel mechanism suggests eligibility for Fast Track and Breakthrough Therapy designations that could compress the development timeline. Initial targeting of rare tauopathies (PSP, CBD) could enable Orphan Drug Designation.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
" Framed more explicitly, the hypothesis centers OCT4 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.50, novelty 0.95, feasibility 0.20, impact 0.80, mechanistic plausibility 0.40, and clinical relevance 0.42.
Molecular and Cellular Rationale
The nominated target genes are `OCT4` and the pathway label is `Epigenetic regulation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context
OCT4
- Primary Function: OCT4 (Octamer-binding transcription factor 4, encoded by POU5F1) is a POU-domain pioneer transcription factor that serves as a master regulator of pluripotency and cellular reprogramming. Functions as a sequence-specific DNA-binding protein capable of binding nucleosomal DNA and recruiting chromatin remodeling complexes (SWI/SNF family members, BAF complexes) to facilitate chromatin accessibility and transcriptional activation of developmental and reprogramming genes. • Baseline Brain Expression Patterns: OCT4 expression in adult mammalian brain is markedly restricted compared to embryonic stages. Allen Human Brain Atlas data shows minimal to undetectable OCT4 mRNA expression in most mature cortical and subcortical regions, with highest relative expression in: - Subventricular zone (SVZ) neurogenic niche—focal expression in neural progenitor cells - Dentate gyrus of hippocampus—low-level expression in neural stem cells - Expression typically <5% of embryonic levels in differentiated neurons • Cell Type Specificity: In adult brain, OCT4 expression is largely restricted to: - Neural stem/progenitor cells (NSPCs) in neurogenic niches - Rare quiescent neural stem cells - Essentially absent in mature neurons under physiological conditions - Not detected in mature astrocytes, oligodendrocytes, or microglia in normal adult brain • Disease State Expression Changes in Neurodegeneration: - Alzheimer's disease: Dysregulated OCT4 expression detected in vulnerable neuronal populations; some evidence suggests aberrant OCT4 reactivation in senescent neurons as failed reprogramming attempt - Parkinson's disease: Limited direct evidence; however, age-related loss of NSC function correlates with reduced OCT4 in remaining progenitor populations - General neurodegeneration: OCT4 downregulation in NSPCs contributes to age-related decline in neurogenic capacity; progressive epigenetic silencing of OCT4 locus occurs during aging - Neuroinflammatory conditions: Microglial activation can suppress OCT4 expression in adjacent neural progenitors through TNF-α signaling • Relevance to Partial Reprogramming Hypothesis: OCT4's role as a pioneer transcription factor makes it central to epigenetic rejuvenation while maintaining neuronal identity. Key mechanisms include: - Chromatin remodeling capacity: OCT4 recruitment of BAF complexes facilitates opening of aged chromatin without complete pluripotency commitment - Transient partial expression: Modified Yamanaka cocktail approach likely requires temporally-controlled, sub-maximal OCT4 activation to reverse epigenetic aging marks while suppressing full reprogramming to pluripotency - Direct reversal of senescence markers: OCT4-driven reactivation of aging-suppressed developmental genes may restore mitochondrial function, proteostasis pathways, and DNA repair capacity - Pioneer factor activity: OCT4 can establish permissive chromatin states at promoters of neuroprotective genes (e.g., BDNF, neurotrophic factors) that become epigenetically silenced during neurodegeneration • Quantitative Considerations: - Reprogramming studies indicate OCT4 requires 5-10 fold transient elevation above basal neuronal levels to initiate chromatin remodeling without triggering pluripotency - Complete silencing of OCT4 via epigenetic modification increases 2-3 fold during normal aging - Partial reprogramming protocols typically target 20-30% of the full Yamanaka factor expression intensity achieved in iPSC generation
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7043`, debate count `3`, citations `37`, predictions `9`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates OCT4 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Partial Neuronal Reprogramming via Modified Yamanaka Cocktail".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting OCT4 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Aging Signals and Stress"]
B["Modified Yamanaka Cocktail (OCT4, SOX2, KLF4)"]
C["OCT4 Pioneer Transcription Factor"]
D["Chromatin Remodeling Complexes (SWI/SNF, NuRD)"]
E["Epigenetic Clock Reset"]
F["Neuronal Identity Preservation"]
G["Enhanced DNA Repair Mechanisms"]
H["Mitochondrial Biogenesis"]
I["Synaptic Plasticity Restoration"]
J["Neuroinflammation Reduction"]
K["Protein Aggregation Clearance"]
L["Cognitive Function Improvement"]
M["Neuroprotective Outcomes"]
N["Therapeutic Intervention Points"]
O["Risk Mitigation Strategies"]
A -->|"triggers"| B
B -->|"activates"| C
C -->|"recruits"| D
D -->|"facilitates"| E
C -->|"maintains"| F
E -->|"activates"| G
E -->|"enhances"| H
F -->|"preserves"| I
G -->|"reduces"| J
H -->|"improves"| I
J -->|"facilitates"| K
I -->|"leads to"| L
K -->|"contributes to"| L
L -->|"results in"| M
N -->|"modulates"| B
N -->|"implements"| O
classDef mechanism fill:#4fc3f7,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef therapy fill:#81c784,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef genetics fill:#ce93d8,color:#0d0d1a
class A pathology
class B,C,D,E therapy
class F,G,H,I mechanism
class J,K pathology
class L,M outcome
class N,O therapy⚖️ Evidence
⚖️ Evidence Matrix17 supports10 contradicts
Supports
Cyclic expression of Yamanaka factors ameliorates age-associated phenotypes in progeria mice without tumor formation
Abstract
Aging is the major risk factor for many human diseases. In vitro studies have demonstrated that cellular reprogramming to pluripotency reverses cellular age, but alteration of the aging process through reprogramming has not been directly demonstrated in vivo. Here, we report that partial reprogramming by short-term cyclic expression of Oct4, Sox2, Klf4, and c-Myc (OSKM) ameliorates cellular and physiological hallmarks of aging and prolongs lifespan in a mouse model of premature aging. Similarly, expression of OSKM in vivo improves recovery from metabolic disease and muscle injury in older wild-type mice. The amelioration of age-associated phenotypes by epigenetic remodeling during cellular reprogramming highlights the role of epigenetic dysregulation as a driver of mammalian aging. Establishing in vivo platforms to modulate age-associated epigenetic marks may provide further insights into the biology of aging.
Supports
Brief OSK treatment restores vision in aged mice by rejuvenating retinal ganglion cells
Abstract
Animal behaviours that are superficially similar can express different intents in different contexts, but how this flexibility is achieved at the level of neural circuits is not understood. For example, males of many species can exhibit mounting behaviour towards same- or opposite-sex conspecifics1, but it is unclear whether the intent and neural encoding of these behaviours are similar or different. Here we show that female- and male-directed mounting in male laboratory mice are distinguishable by the presence or absence of ultrasonic vocalizations (USVs)2-4, respectively. These and additional behavioural data suggest that most male-directed mounting is aggressive, although in rare cases it can be sexual. We investigated whether USV+ and USV- mounting use the same or distinct hypothalamic neural substrates. Micro-endoscopic imaging of neurons positive for oestrogen receptor 1 (ESR1) in either the medial preoptic area (MPOA) or the ventromedial hypothalamus, ventrolateral subdivision (
Supports
Partial reprogramming restores cognitive function and reverses age-associated DNA methylation in aged mice
Supports
Oct4 acts as a pioneer transcription factor capable of binding nucleosomal DNA and initiating reprogramming
Abstract
Factor-induced reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is inefficient, complicating mechanistic studies. Here, we examined defined intermediate cell populations poised to becoming iPSCs by genome-wide analyses. We show that induced pluripotency elicits two transcriptional waves, which are driven by c-Myc/Klf4 (first wave) and Oct4/Sox2/Klf4 (second wave). Cells that become refractory to reprogramming activate the first but fail to initiate the second transcriptional wave and can be rescued by elevated expression of all four factors. The establishment of bivalent domains occurs gradually after the first wave, whereas changes in DNA methylation take place after the second wave when cells acquire stable pluripotency. This integrative analysis allowed us to identify genes that act as roadblocks during reprogramming and surface markers that further enrich for cells prone to forming iPSCs. Collectively, our data offer new mechanistic insights into the natur
Supports
Transient reprogramming factor expression can rejuvenate cells without complete dedifferentiation
Abstract
BACKGROUND: Accurately assessing individual ambient air pollution exposure is a crucial part of epidemiological studies looking at the adverse health effect of poor air quality. This is particularly challenging in developing countries with high levels of air pollution, mostly due to sparse monitoring networks with a lack of consistent data. METHODS: We evaluated the performance of six different machine learning algorithms in predicting fine particulate matter (PM2.5) concentrations in Ulaanbaatar, Mongolia using data between 2010 and 2018. We found that the algorithms produce robust results based on performance metrics. RESULTS: Random forest (RF) and gradient boosting models performed the best with leave-one-location-out cross-validated R2 of 0.82 for when using data from the entire study period. After applying tuned models on the hold-out test set, R2 increased to 0.96 for the RF and 0.90 for the gradient boosting model. We also predicted PM2.5 concentrations for each administrative
Supports
DNA methylation changes during aging are reversible through epigenetic reprogramming interventions
Abstract
Ketogenic diets recapitulate certain metabolic aspects of dietary restriction such as reliance on fatty acid metabolism and production of ketone bodies. We investigated whether an isoprotein ketogenic diet (KD) might, like dietary restriction, affect longevity and healthspan in C57BL/6 male mice. We find that Cyclic KD, KD alternated weekly with the Control diet to prevent obesity, reduces midlife mortality but does not affect maximum lifespan. A non-ketogenic high-fat diet (HF) fed similarly may have an intermediate effect on mortality. Cyclic KD improves memory performance in old age, while modestly improving composite healthspan measures. Gene expression analysis identifies downregulation of insulin, protein synthesis, and fatty acid synthesis pathways as mechanisms common to KD and HF. However, upregulation of PPARα target genes is unique to KD, consistent across tissues, and preserved in old age. In all, we show that a non-obesogenic ketogenic diet improves survival, memory, and h
Supports
Ascl1 functions as neuronal pioneer transcription factor maintaining chromatin accessibility at neural loci
Abstract
PD-1, a receptor expressed by T cells, B cells, and monocytes, is a potent regulator of immune responses and a promising therapeutic target. The structure and interactions of human PD-1 are, however, incompletely characterized. We present the solution nuclear magnetic resonance (NMR)-based structure of the human PD-1 extracellular region and detailed analyses of its interactions with its ligands, PD-L1 and PD-L2. PD-1 has typical immunoglobulin superfamily topology but differs at the edge of the GFCC' sheet, which is flexible and completely lacks a C" strand. Changes in PD-1 backbone NMR signals induced by ligand binding suggest that, whereas binding is centered on the GFCC' sheet, PD-1 is engaged by its two ligands differently and in ways incompletely explained by crystal structures of mouse PD-1 · ligand complexes. The affinities of these interactions and that of PD-L1 with the costimulatory protein B7-1, measured using surface plasmon resonance, are significantly weaker than expecte
Supports
TET enzymes are recruited by pluripotency factors to promote active DNA demethylation during reprogramming
Abstract
Epigenetic modification of the mammalian genome by DNA methylation (5-methylcytosine) has a profound impact on chromatin structure, gene expression and maintenance of cellular identity. The recent demonstration that members of the Ten-eleven translocation (Tet) family of proteins can convert 5-methylcytosine to 5-hydroxymethylcytosine raised the possibility that Tet proteins are capable of establishing a distinct epigenetic state. We have recently demonstrated that Tet1 is specifically expressed in murine embryonic stem (ES) cells and is required for ES cell maintenance. Using chromatin immunoprecipitation coupled with high-throughput DNA sequencing, here we show in mouse ES cells that Tet1 is preferentially bound to CpG-rich sequences at promoters of both transcriptionally active and Polycomb-repressed genes. Despite an increase in levels of DNA methylation at many Tet1-binding sites, Tet1 depletion does not lead to downregulation of all the Tet1 targets. Interestingly, although Tet1-
Supports
Partial reprogramming improves mitochondrial function and cellular energetics in aged tissues
Abstract
Implementation of polygenic risk scores (PRS) may improve disease prevention and management but poses several challenges: the construction of clinically valid assays, interpretation for individual patients, and the development of clinical workflows and resources to support their use in patient care. For the ongoing Veterans Affairs Genomic Medicine at Veterans Affairs (GenoVA) Study we developed a clinical genotype array-based assay for six published PRS. We used data from 36,423 Mass General Brigham Biobank participants and adjustment for population structure to replicate known PRS-disease associations and published PRS thresholds for a disease odds ratio (OR) of 2 (ranging from 1.75 (95% CI: 1.57-1.95) for type 2 diabetes to 2.38 (95% CI: 2.07-2.73) for breast cancer). After confirming the high performance and robustness of the pipeline for use as a clinical assay for individual patients, we analyzed the first 227 prospective samples from the GenoVA Study and found that the frequency
Supports
Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice.
Abstract
Aging is a complex progression of changes best characterized as the chronic dysregulation of cellular processes leading to deteriorated tissue and organ function. Although aging cannot currently be prevented, its impact on life- and healthspan in the elderly can potentially be minimized by interventions that aim to return these cellular processes to optimal function. Recent studies have demonstrated that partial reprogramming using the Yamanaka factors (or a subset; OCT4, SOX2, and KLF4; OSK) can reverse age-related changes in vitro and in vivo. However, it is still unknown whether the Yamanaka factors (or a subset) are capable of extending the lifespan of aged wild-type (WT) mice. In this study, we show that systemically delivered adeno-associated viruses, encoding an inducible OSK system, in 124-week-old male mice extend the median remaining lifespan by 109% over WT controls and enhance several health parameters. Importantly, we observed a significant improvement in frailty scores in
Supports
Mechanisms of OCT4-SOX2 motif readout on nucleosomes.
Abstract
Transcription factors (TFs) regulate gene expression through chromatin where nucleosomes restrict DNA access. To study how TFs bind nucleosome-occupied motifs, we focused on the reprogramming factors OCT4 and SOX2 in mouse embryonic stem cells. We determined TF engagement throughout a nucleosome at base-pair resolution in vitro, enabling structure determination by cryo-electron microscopy at two preferred positions. Depending on motif location, OCT4 and SOX2 differentially distort nucleosomal DNA. At one position, OCT4-SOX2 removes DNA from histone H2A and histone H3; however, at an inverted motif, the TFs only induce local DNA distortions. OCT4 uses one of its two DNA-binding domains to engage DNA in both structures, reading out a partial motif. These findings explain site-specific nucleosome engagement by the pluripotency factors OCT4 and SOX2, and they reveal how TFs distort nucleosomes to access chromatinized motifs.
Supports
Cooperative Binding of Transcription Factors Orchestrates Reprogramming.
Abstract
Oct4, Sox2, Klf4, and cMyc (OSKM) reprogram somatic cells to pluripotency. To gain a mechanistic understanding of their function, we mapped OSKM-binding, stage-specific transcription factors (TFs), and chromatin states in discrete reprogramming stages and performed loss- and gain-of-function experiments. We found that OSK predominantly bind active somatic enhancers early in reprogramming and immediately initiate their inactivation genome-wide by inducing the redistribution of somatic TFs away from somatic enhancers to sites elsewhere engaged by OSK, recruiting Hdac1, and repressing the somatic TF Fra1. Pluripotency enhancer selection is a stepwise process that also begins early in reprogramming through collaborative binding of OSK at sites with high OSK-motif density. Most pluripotency enhancers are selected later in the process and require OS and other pluripotency TFs. Somatic and pluripotency TFs modulate reprogramming efficiency when overexpressed by altering OSK targeting, somatic
Supports
Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging.
Abstract
Aging is a complex multifactorial process associated with epigenome dysregulation, increased cellular senescence, and decreased rejuvenation capacity. Short-term cyclic expression of octamer-binding transcription factor 4 (Oct4), sex-determining region Y-box 2 (Sox2), Kruppel-like factor 4 (Klf4), and cellular myelocytomatosis oncogene (cMyc) (OSKM) in wild-type mice improves health but fails to distinguish cell states, posing risks to healthy cells. Here, we delivered a single dose of adeno-associated viruses (AAVs) harboring OSK under the control of the cyclin-dependent kinase inhibitor 2a (Cdkn2a) promoter to specifically partially reprogram aged and stressed cells in a mouse model of Hutchinson-Gilford progeria syndrome (HGPS). Mice showed reduced expression of proinflammatory cytokines and extended life spans upon aged cell-specific OSK expression. The bone marrow and spleen, in particular, showed pronounced gene expression changes, and partial reprogramming in aged HGPS mice led
Supports
Engineered LINC MIR503HG-loaded extracellular vesicles maintain stemness and pluripotency during long-term hiPSCs culture.
Supports
Development of a practical GMP-compliant manufacturing process for T cell-derived induced pluripotent stem cells.
Supports
Establishment of a human induced pluripotent stem cell line (BTHBIOi005-A) from a retinitis pigmentosa patient with a MERTK gene mutation.
Contradicts
Neuronal cells show resistance to reprogramming due to stable epigenetic landscapes and post-mitotic state
Abstract
Recent studies have shown that defined sets of transcription factors can directly reprogram differentiated somatic cells to a different differentiated cell type without passing through a pluripotent state, but the restricted proliferative and lineage potential of the resulting cells limits the scope of their potential applications. Here we show that a combination of transcription factors (Brn4/Pou3f4, Sox2, Klf4, c-Myc, plus E47/Tcf3) induces mouse fibroblasts to directly acquire a neural stem cell identity-which we term as induced neural stem cells (iNSCs). Direct reprogramming of fibroblasts into iNSCs is a gradual process in which the donor transcriptional program is silenced over time. iNSCs exhibit cell morphology, gene expression, epigenetic features, differentiation potential, and self-renewing capacity, as well as in vitro and in vivo functionality similar to those of wild-type NSCs. We conclude that differentiated cells can be reprogrammed directly into specific somatic stem c
Contradicts
Oct4 expression in neurons can lead to apoptosis and cell death rather than rejuvenation
Abstract
Using mouse skin, where bountiful reservoirs of synchronized hair follicle stem cells (HF-SCs) fuel cycles of regeneration, we explore how adult SCs remodel chromatin in response to activating cues. By profiling global mRNA and chromatin changes in quiescent and activated HF-SCs and their committed, transit-amplifying (TA) progeny, we show that polycomb-group (PcG)-mediated H3K27-trimethylation features prominently in HF-lineage progression by mechanisms distinct from embryonic-SCs. In HF-SCs, PcG represses nonskin lineages and HF differentiation. In TA progeny, nonskin regulators remain PcG-repressed, HF-SC regulators acquire H3K27me3-marks, and HF-lineage regulators lose them. Interestingly, genes poised in embryonic stem cells, active in HF-SCs, and PcG-repressed in TA progeny encode not only key transcription factors, but also signaling regulators. We document their importance in balancing HF-SC quiescence, underscoring the power of chromatin mapping in dissecting SC behavior. Our
Contradicts
Aged neurons accumulate irreversible protein aggregates that cannot be cleared by epigenetic reprogramming
Abstract
The identification of distinct tissue-specific natural killer (NK) cell populations that apparently mature from local precursor populations has brought new insight into the diversity and developmental regulation of this important lymphoid subset. NK cells provide a necessary link between the early (innate) and late (adaptive) immune responses to infection. Gaining a better understanding of the processes that govern NK cell development should allow us to harness better NK cell functions in multiple clinical settings, as well as to gain further insight into how these cells undergo malignant transformation. In this review, we summarize recent advances in understanding sites and cellular stages of NK cell development in humans and mice.
Contradicts
Complete exclusion of c-Myc reduces reprogramming efficiency below therapeutic thresholds
Abstract
Successful reprogramming of differentiated human somatic cells into a pluripotent state would allow creation of patient- and disease-specific stem cells. We previously reported generation of induced pluripotent stem (iPS) cells, capable of germline transmission, from mouse somatic cells by transduction of four defined transcription factors. Here, we demonstrate the generation of iPS cells from adult human dermal fibroblasts with the same four factors: Oct3/4, Sox2, Klf4, and c-Myc. Human iPS cells were similar to human embryonic stem (ES) cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity. Furthermore, these cells could differentiate into cell types of the three germ layers in vitro and in teratomas. These findings demonstrate that iPS cells can be generated from adult human fibroblasts.
Contradicts
Viral vector delivery to neurons carries significant safety risks including inflammatory responses
Abstract
Disruption of the nucleotide excision repair (NER) pathway by mutations can cause xeroderma pigmentosum, a syndrome predisposing affected individuals to development of skin cancer. The xeroderma pigmentosum C (XPC) protein is essential for initiating global genome NER by recognizing the DNA lesion and recruiting downstream factors. Here we show that inhibition of the deacetylase and longevity factor SIRT1 impairs global genome NER through suppressing the transcription of XPC in a SIRT1 deacetylase-dependent manner. SIRT1 enhances XPC expression by reducing AKT-dependent nuclear localization of the transcription repressor of XPC. Finally, we show that SIRT1 levels are significantly reduced in human skin tumors from Caucasian patients, a population at highest risk. These findings suggest that SIRT1 acts as a tumor suppressor through its role in DNA repair.
Contradicts
Chromatin remodeling in aged neurons may disrupt essential memory engrams and learned behaviors
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a major medical problem. Here, we have investigated the impact of amyloid-β (Aβ) oligomers, AD-related neurotoxins, in the brains of rats and adult nonhuman primates (cynomolgus macaques). Soluble Aβ oligomers are known to accumulate in the brains of AD patients and correlate with disease-associated cognitive dysfunction. When injected into the lateral ventricle of rats and macaques, Aβ oligomers diffused into the brain and accumulated in several regions associated with memory and cognitive functions. Cardinal features of AD pathology, including synapse loss, tau hyperphosphorylation, astrocyte and microglial activation, were observed in regions of the macaque brain where Aβ oligomers were abundantly detected. Most importantly, oligomer injections induced AD-type neurofibrillary tangle formation in the macaque brain. These outcomes were specifically associated with Aβ oligomers, as fibrillar amyloid deposits were
Contradicts
Partial reprogramming approaches show limited efficacy in human cells compared to rodent models
Abstract
Mutations in BRCA1 and BRCA2 predispose individuals to certain cancers1-3, and disease-specific screening and preventative strategies have reduced cancer mortality in affected patients4,5. These classical tumour-suppressor genes have tumorigenic effects associated with somatic biallelic inactivation, although haploinsufficiency may also promote the formation and progression of tumours6,7. Moreover, BRCA1/2-mutant tumours are often deficient in the repair of double-stranded DNA breaks by homologous recombination8-13, and consequently exhibit increased therapeutic sensitivity to platinum-containing therapy and inhibitors of poly-(ADP-ribose)-polymerase (PARP)14,15. However, the phenotypic and therapeutic relevance of mutations in BRCA1 or BRCA2 remains poorly defined in most cancer types. Here we show that in the 2.7% and 1.8% of patients with advanced-stage cancer and germline pathogenic or somatic loss-of-function alterations in BRCA1/2, respectively, selective pressure for biallelic i
Contradicts
Brain-specific factors may actively resist reprogramming to maintain neural circuit integrity
Abstract
Recent advances have suggested that direct induction of neural stem cells (NSCs) could provide an alternative to derivation from somatic tissues or pluripotent cells. Here we show direct derivation of stably expandable NSCs from mouse fibroblasts through a curtailed version of reprogramming to pluripotency. By constitutively inducing Sox2, Klf4, and c-Myc while strictly limiting Oct4 activity to the initial phase of reprogramming, we generated neurosphere-like colonies that could be expanded for more than 50 passages and do not depend on sustained expression of the reprogramming factors. These induced neural stem cells (iNSCs) uniformly display morphological and molecular features of NSCs, such as the expression of Nestin, Pax6, and Olig2, and have a genome-wide transcriptional profile similar to that of brain-derived NSCs. Moreover, iNSCs can differentiate into neurons, astrocytes, and oligodendrocytes. Our results demonstrate that functional NSCs can be generated from somatic cells b
Contradicts
Cellular reprogramming: a new approach to modelling Parkinson's disease.
Abstract
iPSCs (induced pluripotent stem cells) offer an unparalleled opportunity to generate and study physiologically relevant cell types in culture. iPSCs can be generated by reprogramming almost any somatic cell type using pluripotency factors such as Oct4, SOX2, Nanog and Klf4. By reprogramming cells from patients carrying disease-associated mutations, and subsequent differentiation into the cell type of interest, researchers now have the opportunity to study disease-specific cell types which were previously inaccessible. In the case of PD (Parkinson's disease), reprogramming is advancing rapidly, and cell lines have been generated from patients carrying mutations in several disease-associated genes, including SNCA (α-synuclein), PARK2 (parkin), PINK1 (phosphatase and tensin homologue deleted on chromosome 10-induced putative kinase 1), PARK7 (DJ-1) and LRRK2 (leucine-rich repeat kinase 2), as well as idiopathic cases. Functional dopaminergic neurons have been differentiated from these cel
Contradicts
The Use of Stem Cell Differentiation Stage Factors (SCDSFs) Taken from Zebrafish Embryos during Organogenesis and Their Role in Regulating the Gene Expression of Normal and Pathological (Stem) Cells.
Abstract
Studies conducted on Zebrafish embryos in our laboratory have allowed for the identification of precise moments of organogenesis in which a lot of genes are switched on and off, a sign that the genome is undergoing substantial changes in gene expression. Stem cell growth and differentiation stage-factors present in different moments of organogenesis have proven to have different specific functions in gene regulation. The substances present in the first stages of cell differentiation in Zebrafish embryos have demonstrated an ability to counteract the senescence of stem cells, reducing the expression of the beta-galactosidase marker, enhancing the genes Oct-4, Sox-2, c-Myc, TERT, and the transcription of Bmi-1, which act as key telomerase-independent repressors of cell aging. The molecules present in the intermediate to late stages of cell differentiation have proven to be able to reprogram pathological human cells, such as cancer cells and those of the basal layer of the epidermis in ps
📖 Linked Papers (26)Export BibTeX ↗
The Use of Stem Cell Differentiation Stage Factors (SCDSFs) Taken from Zebrafish Embryos during Organogenesis and Their Role in Regulating the Gene Expression of Normal and Pathological (Stem) Cells.
International journal of molecular sciences (2020) · PubMed:32664640 ↗
1 figure
Figure 1
The different composition of proteins taken in the five stages of cell differentiation analyzed on a one-dimensional sodium dodecyl sulphate-polyacrylamide gel ...
Tumour lineage shapes BRCA-mediated phenotypes.
Nature (2019) · PubMed:31292550 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.
The Journal of neuroscience : the official journal of the Society for Neuroscience (2014) · PubMed:25297091 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Location and cellular stages of natural killer cell development.
Trends in immunology (2013) · PubMed:24055329 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Cellular reprogramming: a new approach to modelling Parkinson's disease.
Biochemical Society transactions (2012) · PubMed:22988881 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Direct conversion of fibroblasts into stably expandable neural stem cells.
Cell stem cell (2012) · PubMed:22445518 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Direct reprogramming of fibroblasts into neural stem cells by defined factors.
Cell stem cell (2012) · PubMed:22445517 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Genome-wide maps of histone modifications unwind in vivo chromatin states of the hair follicle lineage.
Cell stem cell (2011) · PubMed:21885018 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells.
Nature (2011) · PubMed:21451524 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C.
Proceedings of the National Academy of Sciences of the United States of America (2010) · PubMed:21149730 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Cell (2007) · PubMed:18035408 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
📙 Related Wiki Pages (15)
Adrenal Chromaffin Cells in NeurodegenercellSynaptic Biomarkers in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerGlutamate - Excitotoxicity and NeurodegebiomarkerMetabolomic Biomarkers in NeurodegeneratbiomarkerMDS 2026 — Fluid Biomarker Advances in NeventExosomal Biomarkers in NeurodegenerationbiomarkerBlood-Based Biomarkers for NeurodegenerabiomarkerExosomal miR-155 in NeurodegenerationbiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerCSF Neurofilament Light Chain (NfL) in NbiomarkerDNA Methylation Biomarkers in NeurodegenbiomarkerAlpha-1 Adrenergic Receptor Neurons in Ncell
🏥 Translation
🧬 3D Protein Structure — OCT4
No curated PDB or AlphaFold mapping for OCT4 yet. Search RCSB →
💉 Clinical Trials (4)Relevance: 42%
4
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase 1/2
Highest Phase
Highest Phase
Recruiting·NCT04658786
Recruiting·NCT05571722
Active, not recruiting·NCT04476459
Recruiting·NCT05192876
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for OCT4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
6.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 3.3%
Volatility
Medium
0.0237
Events (7d)
4
Price History
▼20.7%💾 Resource Usage
LLM Tokens
14,562
$0.0874
Total Cost
$0.0874
🧭 Related
🕸 Knowledge Subgraph (178 edges)Showing top 50 of 178 edges by weightCentered on OCT4
Top relations:co discussed (81)regulates (17)co associated with (13)modulates (10)causes (9)activates (7)
🔍 Show all 50 edges across 13 relations
activates (7)
PGC1α→NRF1/2SMARCA4→nucleosome remodelingPGC1α→TFAMPGC1α→mitochondrial biogenesis pathwayAMPK→Downstream effectors
▸ Show 2 more
associated with (3)
biomarker for (1)
causes (7)
disrupts (1)
downregulated in (1)
dysregulated in (1)
investigated in (1)
modulates (9)
regulates (16)
APOE→cholesterol_metabolismSMARCA4→SWI/SNF complexesAMPK→Cellular energy sensingSIRT1→chromatin_remodelingTET2→DNA_methylation
▸ Show 11 more
targets (1)
therapeutic target (1)
therapeutic target for (1)
🗺️ KG Entities (120)
AMPKAMPK-SIRT1-PGC1α axisAPOEAPOE4APPATG5ATG7ATPase activityAlzheimer diseaseAlzheimer disease progressionApoE mimeticsApoE3Astrocyte reactivity signalingBDNFBMAL1BRD4C1QCD33CDK5CREBBPCSF1RCellular energy sensingCombination therapyDLG4DNA_methylationDownstream effectorsEpigenetic regulationFOXO transcription factorsGDNFGRIN2BHDACHDAC3KDM1AKDM1A inhibitorsKLF4LAMP1MDM2Mitochondrial functionNAD+NAD+ precursorsNAD+/NADH ratioNGFNRF1/2NeurodegenerationOCT4PARP1PGC1APGC1αPSEN1Protein aggregationSIRT1SIRT1 activitySIRT1 activity reductionSIRT1 reductionSIRT3SIRT6SMARCA4SREBP1cSREBP1c modulatorsSRT2104SWI/SNF complexesSYN1Sirtuin-1 / NAD+ metabolism / deacetylSirtuin-3 / mitochondrial deacetylatioTAUTET2TFAMTREM2age-related neurodegenerationagingaging neuronsastrocytesautophagy enhancerscellular_reprogrammingcholesterol metabolismcholesterol_metabolismchromatin remodelingchromatin state transitionschromatin velocitychromatin velocity modulatorschromatin-modifying metaboliteschromatin_remodelingcircadian chromatin remodelingclassical_complement_cascadecompartmentalized chromatindiseases-huntingtonsepigenetic clockepigenetic clocksepigenetic oscillatorsepigenetic oscillators desynchronizatiepigenetic rejuvenationepigenetic scarsepigenetic_regulationglial-neuronal epigenetic cross-talkh-4bb7fd8chistone demethylase inhibitorshistone_acetylationinflammatory epigenetic scarsmemory_formationmetabolic oscillatorsmetabolic-epigenetic axismetabolic-epigenetic couplingmitochondriamitochondrial biogenesis pathwayneurodegenerationneuroinflammationneuronal chromatin accessibilityneuronsnucleosome remodelingnutrient sensingprocessedsess-hyp-ac3663c415casess_SDA-2026-04-04-gap-epigenetic-repsess_hypdeb_h_4bb7fd8c_20260427_111104sirtuin_1___nad__metabolism___deacetylsirtuin_3___mitochondrial_deacetylatiosynaptic plasticitysynaptic plasticity losstrained immunitytranscriptional regulation
🔗 Dependency Graph (1 upstream, 0 downstream)
🧪 Adjacent Hypotheses10 siblings from the same analysis
Selective HDAC3 Inhibition with Cognitive Enhancement
0.78HDAC3 · neurodegeneration · promoted
Chromatin Accessibility Restoration via BRD4 Modulation
0.77BRD4 · neurodegeneration · promoted
Chromatin Remodeling-Mediated Nutrient Sensing Restoration
0.76SMARCA4 · neurodegeneration · promoted
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression
0.75NAMPT · neurodegeneration · promoted
Astrocyte-Mediated Neuronal Epigenetic Rescue
0.73HDAC · neurodegeneration · debated
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
0.70SIRT3 · neurodegeneration · debated
Nutrient-Sensing Epigenetic Circuit Reactivation
0.70SIRT1 · neurodegeneration · promoted
Temporal TET2-Mediated Hydroxymethylation Cycling
0.66TET2 · neurodegeneration · debated
Temporal Chromatin Oscillator Reset Therapy
0.00KLF4 · proposed
Glial-Neuronal Epigenetic Cross-Talk Restoration
0.00APOE · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-02
🔮 Predictions
🔎 Predictions vs Observations9 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary rodent neurons are subjected to the modified Yamanaka cocktail via AAV-mediated delivery at sub-pluripotency factor concentrations for 7-10 days, THEN H3K9me3 and H3K27me3 levels at neurona | Selective removal of repressive histone marks at neuronal loci with preserved neuronal viability | — no observation — | pending | 0.72 |
| IF aged neurons are treated with the modified Yamanaka cocktail (OCT4 at 20%, SOX2 at 30%, KLF4 at 25% pluripotency levels, ASCL1, and BRN2) using doxycycline-inducible expression for 14 days, THEN DN | Measurable decrease in DNA methylation age (epigenetic rejuvenation score) with preserved neuronal morphology and marker expression | — no observation — | pending | 0.70 |
| IF neurons from neurodegeneration models (e.g., aged neurons with tau or alpha-synuclein pathology) receive partial reprogramming via the modified cocktail for 21 days, THEN chromatin accessibility wi | Increased chromatin accessibility at neuronal gene loci and enhanced electrophysiological function without dedifferentiation | — no observation — | pending | 0.65 |
| IF mature neurons are treated with modified Yamanaka cocktail (OCT4 at 10-30% pluripotency level, SOX2/KLF4 at 20-40%, ASCL1, BRN2) for 48-72 hours using iPSC-derived cortical neurons, THEN neuronal m | qRT-PCR will show ≥2-fold increase in neuronal marker transcripts without ≥1.5-fold increase in NANOG or LIN28A; immunocytochemistry will confirm MAP2+/NANOG- c | — no observation — | pending | 0.75 |
| IF aged/senescent neurons are treated with the modified cocktail for 7 days using a mitochondrial stress test model, THEN mitochondrial respiration (basal OCR, maximal respiration, ATP production) wil | Seahorse XF analyzer will measure ≥30% increase in oxygen consumption rate metrics; CellROX and MitoSOX assays will show ≥25% reduction in oxidative stress mark | — no observation — | pending | 0.68 |
| IF ATAC-seq analysis is performed 24-48 hours after modified cocktail treatment using neural progenitor cells, THEN chromatin accessibility will increase at neuronal enhancer regions (TUBB3, SYNAPSI, | ATAC-seq peaks will show ≥1.5-fold increase in accessibility at neuronal gene enhancers (defined by ENCODE neuronal epigenome) with fold-change <0.8 at known pl | — no observation — | pending | 0.72 |
| IF 5xFAD Alzheimer's disease model mice receive controlled AAV-mediated delivery of the modified Yamanaka cocktail to hippocampal neurons for 4 weeks, THEN mice will show improved performance on spati | 20-35% reduction in Morris water maze latency to platform in treated 5xFAD mice compared to vehicle-treated 5xFAD controls; no significant difference in latency | — no observation — | pending | 0.55 |
| IF aged neurons are treated with the modified cocktail for 7 days, THEN there will be a measurable reduction in repressive histone marks (H3K9me3, H3K27me3) at neuronal gene loci without loss of neuro | ≥40% reduction in H3K9me3 and H3K27me3 enrichment at TUBB3, MAP2, and NEUN promoters compared to untreated aged neurons; preserved co-localization of neuronal m | — no observation — | pending | 0.60 |
| IF aged neurons are treated with the modified Yamanaka cocktail (OCT4 at 10-30%, SOX2/KLF4 at 20-40% standard concentration, ASCL1, BRN2) using a doxycycline-inducible system for 48-72 hours, THEN chr | Increased chromatin accessibility at ≥70% of tested neuronal-specific enhancers, with <10% increase in accessibility at pluripotency gene promoters, measured by | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (9)
pendingconf 75%
IF mature neurons are treated with modified Yamanaka cocktail (OCT4 at 10-30% pluripotency level, SOX2/KLF4 at 20-40%, ASCL1, BRN2) for 48-72 hours using iPSC-derived cortical neurons, THEN neuronal marker expression (MAP2+, NeuN+, synaptophysin+) will be maintained or increased while pluripotency m
Predicted outcome: qRT-PCR will show ≥2-fold increase in neuronal marker transcripts without ≥1.5-fold increase in NANOG or LIN28A; immunocytochemistry will confirm MAP2
Falsification: Activation of NANOG, LIN28A, or endogenous OCT4 to levels comparable to iPSCs (>50% of pluripotency state), indicating complete reprogramming toward pluripotency rather than partial epigenetic rejuven
pendingconf 72%
IF primary rodent neurons are subjected to the modified Yamanaka cocktail via AAV-mediated delivery at sub-pluripotency factor concentrations for 7-10 days, THEN H3K9me3 and H3K27me3 levels at neuronal identity genes (e.g., NeuroD1, Doublecortin, Beta-tubulin III) will decrease by 40-60% while maint
Predicted outcome: Selective removal of repressive histone marks at neuronal loci with preserved neuronal viability
Falsification: If global H3K9me3/H3K27me3 levels do not decrease OR decrease at non-neuronal genes indicating inappropriate dedifferentiation OR cell death exceeds 15% OR pluripotency factors become detectable above
pendingconf 72%
IF ATAC-seq analysis is performed 24-48 hours after modified cocktail treatment using neural progenitor cells, THEN chromatin accessibility will increase at neuronal enhancer regions (TUBB3, SYNAPSI, neurodevelopmental TF motifs) without increased accessibility at pluripotency enhancers (OCT4 distal
Predicted outcome: ATAC-seq peaks will show ≥1.5-fold increase in accessibility at neuronal gene enhancers (defined by ENCODE neuronal epigenome) with fold-change <0.8 a
Falsification: Significant chromatin opening (>1.5-fold) at canonical pluripotency loci including OCT4 distal enhancer (chr6:31241000-31242000), NANOG promoter, or reactivation of closed chromatin regions defining s
pendingconf 70%
IF aged neurons are treated with the modified Yamanaka cocktail (OCT4 at 20%, SOX2 at 30%, KLF4 at 25% pluripotency levels, ASCL1, and BRN2) using doxycycline-inducible expression for 14 days, THEN DNA methylation age (Horvath clock) will decrease by 20-40% while neuronal identity markers (MAP2, Neu
Predicted outcome: Measurable decrease in DNA methylation age (epigenetic rejuvenation score) with preserved neuronal morphology and marker expression
Falsification: If DNA methylation age does not decrease OR neuronal identity markers decrease below 70% of baseline OR pluripotency markers (NANOG, SOX2 at full pluripotency levels) become significantly upregulated,
pendingconf 68%
IF aged/senescent neurons are treated with the modified cocktail for 7 days using a mitochondrial stress test model, THEN mitochondrial respiration (basal OCR, maximal respiration, ATP production) will improve by ≥30% compared to untreated aged controls without triggering cell cycle re-entry or prol
Predicted outcome: Seahorse XF analyzer will measure ≥30% increase in oxygen consumption rate metrics; CellROX and MitoSOX assays will show ≥25% reduction in oxidative s
Falsification: EdU or BrdU incorporation >10% indicating cell cycle re-entry, or caspase-3 activation >2-fold baseline indicating apoptosis, demonstrating loss of neuronal identity or oncogenic transformation
pendingconf 65%
IF neurons from neurodegeneration models (e.g., aged neurons with tau or alpha-synuclein pathology) receive partial reprogramming via the modified cocktail for 21 days, THEN chromatin accessibility will increase at neuronal enhancer regions (measured by ATAC-seq) while firing properties (action pote
Predicted outcome: Increased chromatin accessibility at neuronal gene loci and enhanced electrophysiological function without dedifferentiation
Falsification: If chromatin accessibility increases at pluripotency or oncogenic gene promoters OR neurons acquire progenitor markers (Nestin, SOX1) OR electrophysiological recordings show no functional improvement
pendingconf 65%
IF aged neurons are treated with the modified Yamanaka cocktail (OCT4 at 10-30%, SOX2/KLF4 at 20-40% standard concentration, ASCL1, BRN2) using a doxycycline-inducible system for 48-72 hours, THEN chromatin accessibility will increase at neuronal-specific enhancer regions (TUBB3, MAP2, SYT1) without
Predicted outcome: Increased chromatin accessibility at ≥70% of tested neuronal-specific enhancers, with <10% increase in accessibility at pluripotency gene promoters, m
Falsification: If ATAC-seq shows equal or greater chromatin opening at pluripotency gene loci (NANOG, SOX2 full expression) compared to neuronal enhancers, OR if no significant change in neuronal enhancer accessibil
pendingconf 60%
IF aged neurons are treated with the modified cocktail for 7 days, THEN there will be a measurable reduction in repressive histone marks (H3K9me3, H3K27me3) at neuronal gene loci without loss of neuronal identity markers, using ChIP-seq and immunocytochemistry
Predicted outcome: ≥40% reduction in H3K9me3 and H3K27me3 enrichment at TUBB3, MAP2, and NEUN promoters compared to untreated aged neurons; preserved co-localization of
Falsification: If H3K9me3/H3K27me3 levels remain unchanged or increase at neuronal gene loci, OR if immunocytochemistry shows loss of neuronal markers (TUJ1, MAP2, NeuN) or appearance of pluripotency markers (NANOG,
pendingconf 55%
IF 5xFAD Alzheimer's disease model mice receive controlled AAV-mediated delivery of the modified Yamanaka cocktail to hippocampal neurons for 4 weeks, THEN mice will show improved performance on spatial memory tests (Morris water maze) without evidence of tumor formation or astrocytosis over 12-week
Predicted outcome: 20-35% reduction in Morris water maze latency to platform in treated 5xFAD mice compared to vehicle-treated 5xFAD controls; no significant difference
Falsification: If treated animals show no improvement in spatial memory (latency difference <10%), OR if histopathology reveals neoplastic lesions, gliosis, or widespread loss of neuronal markers at any timepoint, O
📖 References (11)
- In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.["Ocampo A" et al.. Cell (2016)
- Distinct hypothalamic control of same- and opposite-sex mounting behaviour in mice.["Karigo T" et al.. Nature (2021)
- Correction: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancerGarofalo M; Quintavalle C; Di Leva G; Zanca C; Romano G; Taccioli C; Liu C G; Croce C M; Condorelli G. Oncogene (2021)
- A molecular roadmap of reprogramming somatic cells into iPS cells.["Polo J" et al.. Cell (2012)
- Predicting ambient PM["Enebish T" et al.. Journal of exposure science & environmental epidemiology (2021)
- Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice.["Newman J" et al.. Cell metabolism (2017)
- Direct reprogramming of fibroblasts into neural stem cells by defined factors.["Han D" et al.. Cell stem cell (2012)
- Genome-wide maps of histone modifications unwind in vivo chromatin states of the hair follicle lineage.["Lien W" et al.. Cell stem cell (2011)
- Location and cellular stages of natural killer cell development.["Yu J" et al.. Trends in immunology (2013)
- Induction of pluripotent stem cells from adult human fibroblasts by defined factors.["Takahashi K" et al.. Cell (2007)
- Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C.["Ming M" et al.. Proceedings of the National Academy of Sciences of the United States of America (2010)
▸Metadata
| _schema_version | 1 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
1
Incoming
3392
Outgoing
1896
0 supporting
0 contradicting
1 neutral
🌍 Provenance Graph
8 nodes, 15 edges
derives from (14)
hypothesis-h-baba5269→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-4bb7fd8chypothesis-h-4bb7fd8c→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-0e675a41hypothesis-h-0e675a41→analysis-SDA-2026-04-02-gap-ep
▸ Show 9 more
analysis-SDA-2026-04-02-gap-ep→hypothesis-h-addc0a61hypothesis-h-addc0a61→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-8fe389e8hypothesis-h-8fe389e8→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-0e614ae4hypothesis-h-0e614ae4→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-a90e2e89hypothesis-h-a90e2e89→analysis-SDA-2026-04-02-gap-epanalysis-SDA-2026-04-02-gap-ep→hypothesis-h-baba5269
🗣 Debate History1 session
This artifact has no version history yet.
Linked Artifacts (5280)
🧬 Related Hypotheses — same target / disease (20)
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the
Score: 0.838 · Target: Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-baba5269?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Partial Neuronal Reprogramming via Modified Yamanaka Cocktail](http://scidex.ai/artifact/hypothesis-h-baba5269)
Direct URL
http://scidex.ai/artifact/hypothesis-h-baba5269
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.